AI-based early-warning screening program for prostate and bladder cancer in men in Beijing
Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing
This project will test an AI-driven screening and follow-up system to help detect prostate and bladder cancer earlier in men aged 50 and older who live in Beijing.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT07319923 on ClinicalTrials.gov |
What this trial studies
This observational project will implement an AI-based early-warning and screening pathway that begins with screening in community hospitals, moves definitive diagnosis to secondary hospitals, and directs treatment to tertiary centers. The system will support multi-institutional and multi-terminal sharing of disease information to enable dynamic monitoring, referral tracking, and follow-up. Male permanent residents of Beijing aged 50 and older will be enrolled to complete screening tests and questionnaires and to participate in longitudinal follow-up; no experimental therapy is given. Feasibility and effectiveness of the pathway will be tested using statistical analysis of screening, referral, diagnostic, and outcome data.
Who should consider this trial
Good fit: Ideal participants are Beijing male residents aged 50 or older with life expectancy over 10 years, ECOG performance status 0–2, willing to consent and complete required screening and follow-up procedures.
Not a fit: People with a prior or other existing malignant tumor, active prostatitis or urinary infection, or those unable to cooperate with study procedures may not benefit from this screening program.
Why it matters
Potential benefit: If successful, the program could increase early detection and streamline referrals so more men receive timely diagnosis and treatment.
How similar studies have performed: AI tools have shown promising diagnostic support in prostate cancer imaging and pathology, but large-scale community-based AI early-warning screening systems with multi-institutional data sharing in Beijing are relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male community residents aged 50 years or older; Life expectancy \> 10 years and ECOG performance status of 0-2; Permanent residents of Beijing who are willing to cooperate with researchers in the screening process, complete required tests and questionnaires, and participate in subsequent follow-up; Support for the research project and provision of signed informed consent. Exclusion Criteria: * 1）Presence of any other malignant tumor or pre-existing prostate malignancy; 2）Presence of prostatitis or active infection in other parts of the urinary system; 3）Inability to cooperate with the study procedures or other factors deemed unsuitable for participation in this study.
Where this trial is running
Beijing
- Department of Urology, Peking University First Hospital, Beijing, 100034 — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Zejin Ou
- Email: 1522065106@qq.com
- Phone: 17310018392
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.